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Prostaglandins are lipid mediators that are involved in a plethora of biological processes. In this issue of
Immunity, Coulombe et al. (2014) report that prostaglandin E2 suppresses innate and adaptive immune
responses to influenza virus.Influenza A virus (IAV) is a major human
pathogen that infects millions of people
worldwide every year and causes signifi-
cant mortality. The continued emergence
of new IAV variants and drug-resistant
mutants strongly demands the develop-
ment of more effective antiviral thera-
pies (Medina and Garcı´a-Sastre, 2011).
Detailed insights into themolecular mech-
anisms of IAV pathogenesis are essential
for the identification of potential antiviral
drug targets. One major determinant of
the severity of IAV infection is cell-medi-
ated immunity in the lung.
Alveolar macrophages are key players
in the host defense against IAV and
other respiratory viruses. Upon uptake of
pathogens and recognition of pathogen-
associated molecular patterns (PAMPs),
these cells produce various chemokines
and proinflammatory cytokines, including
type I interferons (IFN-a and IFN-b)
(Hussell and Bell, 2014). Upon secretion,
IFN-a and IFN-b trigger defense mecha-
nisms in infected and uninfected cells via
upregulation of IFN-stimulated genes
(ISGs) and also tailor adaptive immunity.
In addition, alveolar macrophages directly
activate the adaptive immune system by
transporting antigen to draining lymph no-
des or by undergoing apoptosis and sub-
sequent cross-presentation of antigen via
dendritic cells (DCs). The work of Cou-
lombe et al. (2014), presented in this issue
of Immunity, reveals that prostaglandin E2
(PGE2) inhibits these important effector
functions of alveolar macrophages in
response to IAV, resulting in greater
severity of infection (Figure 1).
Prostaglandins are secreted lipid medi-
ators that are generated from arachidonic
acid and are involved in numerous biolog-
ical processes, including smooth muscle
function, vasodilation, and modulation ofimmune and inflammatory responses.
PGE2 can be produced by most cell types
through the coordinated action of two
enzymes, cyclooxygenase and prosta-
glandin E synthase (PGES). Upon secre-
tion, PGE2 signals through binding to
four different receptors, EP1–EP4, in an
autocrine or paracrine manner. Receptor
binding induces the activation of many
signaling pathways and downstream
effector molecules. In the context of
microbial infections, PGE2-induced sig-
naling has been shown to trigger both
proinflammatory and immunosuppressive
responses (Kalinski, 2012).
To explore whether PGE2 participates
in the host defense against IAV,Coulombe
et al. infected mice deficient in micro-
somal (m) PGES-1 (Ptges/) with IAV.
Contrary to expectations, those mice
had lower viral titers and reduced
morbidity compared to wild-type (WT)
mice. Consistent with those observations,
PGE2 amounts in the lung of WT mice
were increased shortly after infection,
and enhanced PGE2 amounts correlated
with higher viral loads and infection
severity. The authors further observed an
early increase in inflammation in the lung
of infected Ptges/ mice, characterized
by elevated pulmonary chemokine and
cytokine amounts, and enhanced recruit-
ment of monocytes and macrophages
to the lung, compared with infected WT
animals. These results provided the first
hint that PGE2 suppresses the innate
immune response to IAV.
Type I IFN production by alveolar mac-
rophages is a key component of innate
immunity to IAV (Ho¨gner et al., 2013).
Thus, the authors asked whether the
resistance to IAV infection observed in
Ptges/ mice is due to a more effective
IFN-mediated immune response. Indeed,Immunityinfected Ptges/ alveolar macrophages
produced higher amounts of type I IFN
than cells from WT mice, indicating that
PGE2 suppresses IFN induction. This
inhibitory effect of PGE2 on IFN produc-
tion was mediated by the PGE2 receptors
EP2 and EP4, as well as the phosphatidyl-
inositol 3-kinase (PI3K)-Akt pathway
and protein kinase A (PKA). In support
of this, Ptges/ macrophages showed
a more rapid phosphorylation of the
transcription factor interferon-regulatory
factor 3 (IRF3) following IAV infection,
a critical step in the activation of the IFN
induction pathway.
The described experiments showed
that IFN production in response to IAV
infection is blocked by PGE2 in isolated
alveolar macrophages. But are these
findings also important for the control of
IAV infection in vivo? To address this
question, the authors adoptively trans-
ferred Ptges/ or WT macrophages into
naive WT mice and then challenged the
animals with IAV. Transfer of Ptges/
macrophages, but not WT macrophages,
resulted in higher amounts of type I IFN,
which correlated with lower viral loads
and increased survival. Because PGE2 is
produced by both alveolar macrophages
and lung epithelial cells, the authors
determined the contribution of alveolar
macrophages in PGE2-mediated innate
immune suppression. Depletion of alve-
olar macrophages from Ptges/ mice
increased viral titers to comparable levels
as observed in nondepleted WT animals,
indicating the essential role of alveolar
macrophages in innate immune inhibi-
tion by PGE2.
The authors also observed higher levels
of apoptosis and apoptotic vesicles in
IAV-infected Ptges/ macrophages
compared to IAV-infected WT40, April 17, 2014 ª2014 Elsevier Inc. 453
Figure 1. PGE2, Produced upon IAV Infection, Leads to the Suppression of Innate and
Adaptive Immune Effector Functions in Alveolar Macrophages
Upon IAV infection, PGE2 is secreted from alveolar macrophages and then acts in either an autocrine
(not depicted) or paracrine manner on macrophages. Binding of PGE2 to its receptors EP2 and EP4
activates intracellular PI3K-Akt and/or PKA signaling pathways. PGE2-induced downstream signaling
leads to inhibition of (1) IRF3-mediated type I IFN induction, (2) antigen presentation and T cell activation,
and (3) apoptosis and antigen cross-presentation, ultimately suppressing innate and adaptive immunity
to IAV. P-IRF3 indicates phospho-IRF3.
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Previewsmacrophages. Because it has been re-
ported that antigen from apoptotic vesi-
cles can be taken up by DCs and cross-
presented to T cells (Winau et al., 2006),
the authors next asked whether increased
macrophage apoptosis in Ptges/ mice
might contribute to the activation of the
adaptive immune response. Indeed, the
numbers of both CD4+ and CD8+ T cells
in the lymph nodes and lung of Ptges/
mice were elevated compared to WT ani-
mals, which was associated with
increased amounts of chemokines impor-
tant for T cell recruitment, such as CXCL9
and CXCL10. In vitro experiments further
showed that PGE2 inhibits both the
cross- and direct priming of T cells
through suppression of virus-induced
type I IFN production.
Finally, the authors addressed the
important question of whether pharma-
cological inhibition of PGE2 synthesis454 Immunity 40, April 17, 2014 ª2014 Elsevcould serve as a therapeutic agent
against IAV infection. To test this, the
authors challenged WT mice with a lethal
dose of IAV and subsequently adminis-
tered a specificmPGES-1 inhibitor. Inhibi-
tion of mPGES-1 significantly enhanced
the survival of mice. The inhibitor was
still effective when administered 2 or
3 days after infection, indicating a good
therapeutic potential of specific PGE2
inhibition. Thus, these results might stim-
ulate research on further testing of spe-
cific mPGES-1 inhibitors as influenza
therapeutics.
Although this study greatly expands our
knowledge about the role of PGE2 in the
modulation of host immune responses to
IAV, several important questions remain
unanswered, including: What is the
trigger for PGE2 induction in alveolar
macrophages following IAV infection,
and which innate immune sensors andier Inc.intracellular pathways lead to PGE2 in-
duction? The authors show that the inhibi-
tion of type-I IFN by PGE2 was dependent
on active virus replication, because
neither UV-inactivated IAV, nor synthetic
ligands of the cytosolic viral RNA receptor
RIG-I, were sufficient to trigger PGE2-
mediated IFN suppression. Future work
is needed to elucidate how IAV triggers
PGE2 production, and whether IAV pro-
teins actively modulate PGE2 amounts
to evade IFN-mediated host immunity.
Furthermore, despite the fact that airway
epithelial cells, the main target cells of
IAV replication, are known to produce
PGE2, the authors did not observe a direct
inhibitory effect of PGE2 on IFN produc-
tion and influenza restriction in this cell
type. This raises the question of what
determines the cell specificity of PGE2-
mediated IFN inhibition in alveolar macro-
phages in response to IAV infection.
Finally, it will be important to investigate
the immunomodulatory role of PGE2 in
other respiratory viral infections. Taken
together, the study by Coulombe et al.
has not only provided important insights
into the regulation of innate and adaptive
immunity by prostaglandins but has also
identified the mPGES-1-PGE2 pathway
as a potential target for therapeutic inter-
vention against IAV infection.
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